NEWSCENTRAL reports that Merck & Co, a leader in the pharmaceutical market, has recently presented its forecasts for 2026, which are overshadowed by optimistic results from the fourth quarter. Analysts note that despite strong quarterly performance, the company will face significant challenges related to the loss of exclusive rights to several key drugs, including Januvia, a diabetes medication, as well as other aging drugs.
In the fourth quarter of 2025, Merck surpassed profit and revenue expectations, driven by high demand for its cancer immunotherapy drug, Keytruda. However, this success does not compensate for the weaker outlook for 2026. The company’s revenue forecast for 2026 is between $65.5 billion and $67.0 billion, lower than the average analyst estimate of $67.6 billion. According to analysts, this forecast may lower expectations for both profit and revenue for the entire year.
BMO Capital analysts, in particular, emphasize that despite a strong finish to 2025, the company is entering a period of uncertainty. Freddy Miller, Senior Analyst at NEWSCENTRAL, points out that the loss of exclusivity for drugs like Januvia and Janumet, along with potential consequences for other traditional medications, will require the company to develop new strategies to maintain growth.
According to the report, the company is expecting losses of $2.5 billion in 2026, mainly due to competition from generics, the negative impact of Medicare negotiations, and decreased demand for the COVID-19 drug Lagevrio. These factors make the company’s outlook less certain, especially in light of the threat that the loss of patents on popular drugs may negatively affect financial results.
Nonetheless, Merck’s management remains optimistic about the future, focusing on long-term opportunities. CEO Rob Davis stated that Merck will continue to explore expansion opportunities in areas such as oncology, cardiometabolism, and immunology. The company is actively seeking opportunities for large deals in these fields and plans to provide investors with detailed information about new products by the end of 2027.
Merck will also continue to actively pursue deals in oncology, where the company sees significant potential. In particular, in 2025, Merck made deals worth approximately $10 billion, acquiring companies such as Cidara Therapeutics and Verona Pharma. These moves strengthen the company’s position beyond Keytruda, whose patent is set to expire later this decade.
Despite the forecasted challenges, Merck’s stock rose nearly 3%, indicating investor confidence in the company’s future. Experts from NEWSCENTRAL suggest that this could signal that the market has already factored in the risks associated with patent expirations and is focusing on potential future deals and long-term growth.
In the face of these challenges, it is important to note that Merck is not giving up and is actively working to move beyond older medications, transitioning to more promising and innovative solutions in cancer treatment and other diseases. At NEWSCENTRAL, we believe that the company’s future will depend on its ability to effectively diversify its pipeline and find new growth niches.
Merck will face a number of difficulties in the coming years but also has plenty of strategies and opportunities to sustain its growth. We at NEWS CENTRAL forecast that effective risk management and timely introduction of new drugs will allow the company to overcome current difficulties and return to steady growth in the mid-term.